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Controlled Trial of Supervised Exercise,
Angioplasty, and Combined Therapy
in Intermittent ClaudicationF.A.K. Mazari, S. Gulati, M.N.A. Rahman, H.L.D. Lee, T.A. Mehta, P.T. McCollum,
and I.C. Chetter, Hull, United KingdomBackground: To compare angioplasty (PTA), supervised exercise (SEP) and PTA + SEP in the
treatment of intermittent claudication (IC) due to femoropopliteal disease.
Methods: Over a 6-year period, 178 patients (108 men; median age, 70 years) with femoropo-
pliteal lesions suitable for angioplasty were randomized to PTA, SEP, or PTA + SEP. Patients
were assessed prior to and at 1 and 3 months post treatment. ISCVS outcome criteria (ankle
pressures, treadmill walking distances) and quality of life (QoL) questionnaires (SF-36 and Vas-
cuQoL) were analyzed.
Results: All groups were well matched at baseline. Twenty-one patients withdrew. Results are
as follows: Intragroup analysis: All groups demonstrated significant clinical and QoL improve-
ments (Friedman test, p< 0.05). SEP (60 patients, 8 withdrew)d62.7% of patients (n¼ 32)
improved following treatment [20 mild, 9 moderate, 3 marked], 27.4% (n¼ 14) demonstrated
no improvement, and 9.8% (n¼ 5) deteriorated. PTA (60 patients, 3 withdrew)d66.6% patients
(n¼ 38) improved following treatment [19 mild, 10 moderate, 9 marked], 22.8% (n¼ 13) demon-
strated no improvement, and 10.5% (n¼ 6) deteriorated. PTA + SEP (58 patients, 10 with-
drew)d81.6% of patients (n¼ 40) improved following treatment [10 mild, 17 moderate,
3 marked], 14.2% (n¼ 7) demonstrated no improvement, and 4.0% (n¼ 2) deteriorated. Inter-
group analysis: PTA + SEP produce a much greater improvement in clinical outcome measures
than PTA or SEP alone, but there was no significant QoL advantage (Kruskal-Wallis test,
p> 0.05).
Conclusion: SEP should be the primary treatment for the patients with claudication and PTA
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Peripheral arterial occlusive disease (PAD) is
common, affecting 5% of people over the age of
55 years.1 Intermittent claudication (IC) is the
most frequent clinical presentation with symptoms
varying according to the site and severity of PAD.
Percutaneous transluminal angioplasty (PTA) has
long been established as the treatment of choice in
aortoiliac PAD but there is no current consensus
for the treatment of IC due to infrainguinal PAD.2
Evidence for treatment efficacy of supervised exer-
cise program (SEP) over PTA is scarce, and it is
unclear if combining both treatments gives addi-
tional benefit. Two prospective randomized trials
comparing PTA with SEP in infrainguinal disease3-5
were limited by small patient numbers. A Cochrane
Review on this subject also highlighted difficulties
related to lack of blinding and possibility of bias.69
Table I. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Symptomatic unilateral IC Critical ischemia
Angioplastiable lesion (ss
discussed in MDT)
Severe limitation of
physical activity due to
systemic disease
Femoropopliteal lesion Inability to tolerate
treadmill testing
(unrelated to limb
ischemia)
>3 mo on BMT Significant ischemic ECG
during treadmill testing
70 Mazari et al. Annals of Vascular SurgeryThe review further emphasized the need for larger
trials.6 Furthermore, current evidence suggests
that changes in walking distances are poorly corre-
lated with changes in quality of life, which must
therefore be studied directly with quality of life
(QoL) instruments.7 Moreover, generic QoL and
disease-specific QoL need to be assessed
separately.7,8
This single-center prospective randomized
controlled trial was designed to investigate whether
patientswith IC secondary to femoropopliteal lesions
are best treated with SEP, PTA, or a combination.Ipsilateral surgery,
previous 6 mo
Ipsilateral angioplasty,
previous 6 mo
See text for abbreviations.PATIENTS AND METHODS
Between September 2002 and April 2007, patients
were seen in consultant-led vascular outpatient
clinics. All patients with symptomatic unilateral
infrainguinal disease claudication were referred for
assessment of suitability for inclusion in this trial.
Patients underwent duplex ultrasonography
and/or angiography to assess the site and nature of
their disease. All scans were discussed in a multidis-
ciplinary vascular team (MDT)meeting consisting of
a vascular surgeon, interventional radiologist,
specialist vascular nurse, and vascular technologist,
and only those with unilateral disease suitable for
angioplasty were managed conservatively for
3 months as noted later.
All patients were prescribed antiplatelet therapy
(aspirin and/or clopidogrel), received smoking
cessation advice and support (including nicotine
replacement therapy and NHS smoking cessation
program), and risk factor modification (target
oriented management of hypertension, hypercho-
lesterolemia, and diabetes according to evidence-
based care pathways within a dedicated clinic). All
patients also received an advice leaflet regarding
exercise. These changes were monitored by the
patient’s general practitioner and consultant
vascular surgeon on an outpatient basis. At the end
of the 3 months, patients whose symptoms were
stable on this regimen were included in the trial
and were randomized, using sealed envelopes, to
one of the three treatments; PTA, SEP, or PTA + SEP.
Inclusion criteria and exclusion criteria are summa-
rized in Table I.Interventions by Patient GroupsPercutaneous Transluminal Angioplasty. PTA was
performed by a consultant vascular radiologist as
per normal operating practice at a dedicated
vascular radiology suite in a tertiary referral center.
Contralateral up and over access was used in allcases followed by angiogram and balloon angio-
plasty. Primary stenting or adjunctive procedures
were not performed in any case.
Supervised Exercise Program. SEP patients
attended three sessions of supervised exercise per
week, for a total of 12 weeks. Each session started
with some gentle warm-up exercises followed by
a circuit of exercise stations. For the first 6 weeks,
patients completed one full circuit; thereafter, the
circuit was increased by one station per week,
with the result that by the end of the exercise
program, patients were completing 12 stations per
session. Patients spent 2 minutes at each exercise
station and performed 2-minute walking circuits
between exercise stations. The sessions ended with
gentle stretching and cool-down exercises. All
sessionswere supervised by trained physiotherapists
or physicians.
There were six exercise stations, arranged in the
following order:
Station 1: Walking up and down a 6-inch step
Patients started with the left foot first, and then
changed the starting foot every 10 steps. This was
continued for 2 minutes
Station 2: Double heel raise
Standing erect, with both feet flat on the floor
and holding hand rails for support, patients stood
on tiptoes. This was held for approximately 2
seconds; then the patient slowly returned their
weight to the floor. This was repeated for 2 minutes.
Station 3: Single leg press
Patients stood on one leg between two parallel
bars, used for stability rather than weight-bearing,
and slowly lowered their weight by flexing the
knee of the standing leg, then straightened the leg
Table II. ISCVS outcome criteria
Outcome Description
+3 Marked improvement No ischemic symptoms, any foot lesions healed, ABI normalized (>0.90)
+2 Moderate improvement Improved by at least 1 category and ABI improved by >0.10
+1 Mild improvement ABI improved by >0.10 but no categorical improvement or vice versa
0 No change No categorical shift and <0.10 change in ABI
1 Mild deterioration ABI decrease >0.10 but no categorical deterioration or vice versa
2 Moderate deterioration One category worse or unexpected minor amputation
3 Marked deterioration More than one category worse or unexpected major amputation
See text for abbreviations.
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contra lateral leg was exercised.
Station 4: Exercise bicycle
The patients pedaled for 2 minutes on an exercise
bicycle. Exercise resistancewas sufficient to produce
perspiration and dyspnea but still allowing conver-
sation in complete sentences.
Station 5: Knee extension
Patients sat on a high stool, knees flexed, with
2.5-kg weights attached to each ankle. One leg
was slowly straightened to maximum extension,
before being slowly returned to 90 degrees of
flexion. Ten repetitions were performed with each
leg in alternating fashion for 2 minutes.
Station 6: Elbow flexion
While holding 1.5-kg dumbbells, patients flexed
and extended their elbows for 2 minutes.
This was a validated exercise regimen with estab-
lished clinical and cost effectiveness.9
Combined Therapy (PTA + SEP)
Patients received PTA as described and then were
enrolled into an SEP in the following week.AssessmentsPatients were assessed preintervention (Visit 0) and
at 1 and 3 months postintervention (Visits 1 and 3,
respectively).
Clinical Indicators of Lower Limb Ischemia. At
each assessment visit, patient reported walking
distance (PRWD) was recorded to a maximum of
1000 m. Ankle brachial pressure index (ABIRe)
was measured using a standard sphygmomanom-
eter and a handheld Doppler flow detector with an
8-MHz probe (Huntleigh Technology plc, Cardiff,
UK).
Treadmill Exercise Test. Subjects then underwent
a standardized, constant-load treadmill exercise
test (2.5 km/hr at a 10-degree incline) for
a maximum of 5 minutes. Intermittent claudication
distance (ICD) and maximal treadmill walking
distance (MWD) were recorded up to a maximum
of 207 m (equivalent of 5 minutes walking).Following treadmill testing, postexercise ABI
(ABIPE) was measured using the method described
above.
Outcome following treatment was assessed using
the International Society of Cardiovascular Surgery
(ISCVS) outcome criteria (Table II).10
Quality of Life and Effect Sizes. At each visit,
patients completed questionnaires to assess QoL.
Generic and disease-specific QoL was analyzed
using the MOS Short-Form 36 (SF-36) instrument
and the Kings College VascuQoL questionnaire,
respectively. Both are standard questionnaires that
have been demonstrated to be valid, reliable, and
responsive specifically in patients with IC.11,12
Effect sizes supplement standard statistical testing
to give a more complete and relevant picture of
health status change.13 Effect size is calculated by
dividing the difference between the median value
before and after treatment, by the pretreatment
interquartile range (IQR). An effect size greater
than 0.5 is considered clinically relevant.13Sample Size CalculationsFor sample size calculations, we used an alpha of 5%
and calculated for 80% power, giving a K (constant)
value of 7.9. A 20% change in the outcomemeasure
was considered significant. Calculations were per-
formed for the following outcomes:
1. Walking distances: ICD and MWD
2. ABPI
3. Generic quality of life: SF-36
4. Disease-specific quality of life: VascuQol
We obtained results from previously published
studies and, using the above values, calculated
sample sizes for all primary outcome measures.
The largest sample size was calculated from the
SF-36 domains. Based on previously published
data,14 the mean score of physical functioning
domain (SF-36) in a group of claudicants is 43
(SD, 17.7), which improved to 52 (SD, 22.2) with
Table III. Patient profile preintervention
SEP (n¼ 60) PTA (n¼ 60) PTA + SEP (n¼ 58) p value*
Male (n) 37 37 33 0.6590
Median age (IQR) (yr) 69 (63e76) 70 (63e75) 69.5 (64e79) 1.0000
Diabetic (n) 9 8 8 0.9210
Hypertensive (n) 40 40 34 0.5610
Hypercholesterolemia (n) 47 45 43 0.7050
Smoking (n) 18 18 19 0.9720
PRWDa (m) 100 (50e200) 150 (81e300) 150 (69e300) 0.2693
ABIRea 0.65 (0.53e0.80) 0.70 (0.57e0.87) 0.65 (0.53e0.86) 0.4735
ICDa (m) 33.5 (18.7e62.1) 27.4 (19.2e65.9) 40.0 (20.7e67.6) 0.4185
MWDa (m) 46.2 (32.0e85.4) 51.8 (33.6e81.9) 63.1 (40.2e98.0) 0.4565
ABIPEa 0.31 (0.25e0.56) 0.41 (0.26e0.57) 0.44 (0.22e0.59) 0.3429
SFe36 PFa 30 (20e55) 35 (25e55) 40 (20e50) 0.5950
SFe36 RPa 20 (20e50) 25 (0e65) 25 (0e75) 0.1916
SFe36 BPa 41 (22e64) 41 (31e71) 41 (31e62) 0.5950
SFe36 GHa 55 (35e72) 57 (35e72) 55 (42e67) 0.9671
SFe36 Va 45 (35e55) 50 (35e70) 45 (35e56) 0.3140
SFe36 SFa 62 (37e87) 75 (50e100) 62 (52e87) 0.3108
SFe36 ERa 33 (0e100) 66 (0e100) 66 (33e100) 0.1070
SFe36 MHa 68 (56e84) 72 (56e84) 70 (59e84) 0.6760
SFe36 Indexa 0.57 (0.53e0.62) 0.59 (0.52e0.69) 0.63 (0.52e0.69) 0.5000
VascuQola 3.7 (2.7e5.0) 4.3 (3.3e5.1) 4.2 (2.9e5.2) 0.2342
See text for abbreviations.
aMedian (range).
*Kruskal-Wallis ANOVA.
Table IV. ISCVS outcome by treatment groups
ISCVS outcome (n)
Treatment
arm
Marked
improvement (+3)
Moderate
improvement (+2)
Mild
improvement (+1)
No
change(0)
Mild
deterioration(e1)
SEP 3 9 20 14 5
PTA 9 10 19 13 6
PTA + SEP 13 17 10 7 2
See text for abbreviations.
72 Mazari et al. Annals of Vascular Surgeryintervention. Thus, a change of at least 10 points
(20% to 25% of base value) would be worth detect-
ing. The required sample size for 80% power is 50
patients. Considering 20% dropout, we aimed to
recruit 60 patients in each arm of the study.Data and Statistical AnalysisData were recorded in Excel 2002 for Windows
(Microsoft Corp.) and analyzed using SPSS for
Windows, version 16.0 (SPSS Corp.).
Nonparametric statistical tests were used
throughout the study after appropriate testing for
normality. Intergroup analysis was performed at
each time point using the Kruskal-Wallis analysis
of variance (ANOVA) and Mann-Whitney test.Intragroup analysis was performed using Friedman
test to compare differences over the time course of
the study andWilcoxon signed rank test to compare
differences between each pair of time points.
This study was approved by the local research
ethics committee and the NHS Trust R&D
Committee, and each patient gave informed consent
prior to participating in this study.RESULTS
There were 1157 patients assessed, of whom 185
(16%) had inflow rather than femoropopliteal
disease, 324 (28%) were unsuitable for angioplasty
after discussion in the MDT meeting, and 81 (7%)
PTA+SEPPTASEP
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Fig. 1. Patient reported walking (PRWD).
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Fig. 2. Resting ankle brachial pressure index (ABIRe).
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Fig. 3. Treadmill intermittent claudication distance
(ICD).
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Fig. 4. Maximal treadmill walking distance (MWD).
Vol. 24, No. 1, January 2010 Intermittent claudication from femoropopliteal disease 73had infragenicular disease. Of the remaining 414
patients, 236 (20%) had symptomatic improvement
on best medical treatment, and 153 (13%) patients
declined to participate.
One hundred seventy-eight patients (15.3%)
were recruited and randomized into the three treat-
ment arms (PTA, 60; SEP, 60; PTA + SEP, 58). No
significant difference was observed at baseline
between the three groups in terms in demographic
factors, comorbidities, and QoL ( p> 0.05, Kruskal-
Wallis ANOVA; Table III).
Twenty-one patients (11.7%) withdrew over the
course of the study, of whom 4.4% (n¼ 8) were
from the SEP group, 1.6% (n¼ 3) were from the
PTA group, and 5.6% (n¼ 10) were from the
PTA + SEP group. Arterial duplex at 3 months
demonstrated significant postangioplasty restenosis(doubling of peak systolic velocity used as standard
measure) in 11 patients: 7 from the PTA group and
4 from the PTA + SEP group. None of these patients
required revascularization at this point.Intragroup AnalysesClinical Outcome (ISCVS Score: Table IV)
 SEP: 62.7% of patients improved following treat-
ment, 27.4% demonstrated no change, and 9.8%
deteriorated.
 PTA: 66.6% of patients improved following treat-
ment, 22.8% demonstrated no change, and
10.5% deteriorated.
PTA+SEPPTASEP
Treatment Arm
1.0
0.8
0.6
0.4
0.2
0.0
Month 3Month 1Pre-treatment
Fig. 5. Postexercise ankle brachial pressure index
(ABIPE).
74 Mazari et al. Annals of Vascular Surgery PTA + SEP: 81.6% of patients improved following
treatment, 14.2% demonstrated no change, and
4.0% deteriorated.
Clinical Indicators of Lower Limb Ischemia
(PRWD, ABIRe, ICD, MWD, ABIPE: Figs. 1-5;
Table V). Patients in all three groups demonstrated
increased PRWD, ABIRe, ICD, MWD, and ABIPE
over baseline at 3 months. This was statistically
significant (Wilcoxon signed rank test, p< 0.05).
Quality of Life: SF-36 Domains, SF-36 Index, and
VascuQoL (Table V). SEP patients had statistically
significant improvements in SF-36 domain scores
for Physical Function (PF), Role Physical (RP),
Role Emotional (RE), and Vitality (V) but not in
the domains of Bodily Pain (BP), General Health
(GH), Social Functioning (SF), and Mental Health
(MH). Statistically significant improvements were
also seen in SF-36 index and VascuQol scores.
PTA patients had statistically significant improve-
ments in SF-36 domain scores for BP, PF, RP, and
MH but not in the domains of GH, V, SF, and ER.
Statistically significant improvements were also
observed in the SF-36 index and VascuQol scores.
PTA + SEP patients had statistically significant
improvements in the SF-36 domain scores for PF,
RP, BP, SF, V, and MH but not in the domains of
GH and ER. Statistically significant improvements
were also observed in the SF-36 index and VascuQol
scores.Intergroup AnalysesClinical Outcome ISCVS Score (Table VI,
Fig. 6). When the groups were compared at 3months, PTA + SEP patients demonstrated signifi-
cantly better ISCVS outcome criteria scores than
SEP and PTA (Mann-Whitney U test, p< 0.05). No
significant difference was found between the SEP
and PTA groups.
Clinical Indicators of Lower Limb Ischaemia
 SEP vs. PTA: Over the duration of this study, SEP
patients did not show a significant difference in
any of the clinical indicators of lower limb
ischemia from patients undergoing PTA.
 SEP vs. PTA + SEP: Patients undergoing PTA + SEP
had significantly greater improvements than SEP
patients in all the clinical indicators of lower limb
ischemia (PRWD, ABIRe, ICD, ABIPE) except
MWD.
 PTA vs. PTA + SEP: Patients undergoing PTA + SEP
had significantly greater improvement in all the
clinical indicators of lower limb ischemia (ABIRe,
ICD, MWD, ABIPE) except PRWD.
Quality of Life (Effects Size, Table VI, Fig. 7)
 SEP vs. PTA: Both these treatments resulted in
significant improvements (effect size >0.5) in
the SF-36 domains of PF and BP and the Vascu-
Qol. SEP was superior to PTA in the SF-36
domains of RP, V, and RE and in the SF-36
index. PTA was superior to SEP only in the SF
domain of SF.
 SEP vs. PTA + SEP: Both these treatments resulted
in significant improvements (effect size >0.5) in
the SF-36 domains of PF, RP, BP, V, and RE
and the VascuQol. SEP was superior to PTA + -
SEP in the SF-36 index, while PTA + SEP was
superior in the SF-36 domains of SF and MH.
 PTA vs. PTA + SEP: Both these treatments resulted
in significant improvements (effect size >0.5) in
the SF-36 domains of PF, BP, and SF and the Vas-
cuQol. PTA + SEP was superior to PTA in the SF-
36 domains of RP, V, RE, and MH, while PTA did
not demonstrate superiority to PTA + SEP in any
domain. There was no improvement (effect size
<0.5) in the SF-36 index with PTA or PTA + SEP.
Interestingly, there was no significant improve-
ment (effect size <0.5) in the SF-36 domain of
GH following any of the three interventions.DISCUSSION
Treatment options for patients with infrainguinal
peripheral arterial disease are pharmacotherapy,
SEP, PTA, or surgery. Due to the lack of consensus,
current practice in the United Kingdom is highly
Table V. Results of intragroup analysis for clinical and QoL variables
SEP PTA PTA + SEP
Visit 0 Visit 3 Visit 0 Visit 3 Visit 0 Visit 3
PRWD (m) 100 (50e200) 400 (100e800)* 150 (81e300) 500 (200e1000)* 150 (69e300) 880 (325e1000)*
ABIRe 0.65 (0.53e0.80) 0.8 (0.65e0.94)* 0.70 (0.57e0.87) 0.84 (0.69e0.99)* 0.65 (0.53e0.86) 0.97 (0.78e1.00)*
ICD (m) 33.5 (18.7e62.1) 61.2 (24.9e165.6)* 27.4 (19.2e65.9) 59.0 (33.0e96.0)* 40.0 (20.7e67.6) 108.0 (40.0e207.0)*
MWD (m) 46.2 (32.0e85.4) 92.8 (49.3e207.0)* 51.8 (33.6e81.9) 87.0 (61.0e207.0)* 63.1 (40.2e98.0) 207.0 (71.4e207.0)*
ABIPE 0.31 (0.25e0.56) 0.50 (0.33e0.71)* 0.41 (0.26e0.57) 0.57 (0.35e0.77)* 0.44 (0.22e0.59) 0.68 (0.54e0.91)*
SF-36 PF 30 (20e55) 55 (27e75)* 35 (25e55) 52 (35e75)* 40 (20e50) 60 (36e79)*
SF-36 RP 5 (0e50) 25 (0e100)* 25 (0e65) 25 (00e75)* 25 (0e75) 75 (25e100)*
SF-36 BP 41 (22e64) 55 (32e75) 41 (31e71) 61 (38e84)* 41 (31e62) 62 (42e74)*
SF-36 GH 55 (35e72) 60 (42e72) 57 (35e72) 54 (35e76) 55 (42e67) 62 (47e67)
SF-36 V 45 (35e55) 50 (35e70)* 50 (35e70) 55 (35e70) 45 (35e56) 55 (40e70)*
SF-36 SF 62 (37e87) 75 (50e100) 75 (50e100) 88( 50e100) 62 (52e87) 75 (50e100)*
SF-36 ER 33 (0e100) 83 (0e100)* 66 (0e100) 100 (0e100) 66 (33e100) 83 (33e100)
SF-36 MH 68 (56e84) 72 (62e92) 72 (56e84) 82 (67e92)* 70 (59e84) 82 (65e92)*
SF-36 Index 0.57 (0.53e0.62) 0.64 (0.57e0.79)* 0.59 (0.52e0.69) 0.63 (0.57e0.76)* 0.63 (0.52e.69) 0.68 (0.60e0.75)*
VascuQol 3.7 (2.7e5.0) 5.24 (4.08e6.16)* 4.3 (3.3e5.1) 5.36 (4.51e6.52)* 4.2 (2.9e5.2) 5.80 (4.88e6.40)*
All values expressed as median (range).
See text for abbreviations.
*Wilcoxon rank sum test, p< 0.05.
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76 Mazari et al. Annals of Vascular Surgeryvariable with some units initially treating IC with
medical treatment and exercise advice using inva-
sive procedures like PTA if exercise fails to alleviate
symptoms and others using PTA and other invasive
treatments routinely as first-line therapy.
PTA is a commonly performed procedure with its
own limitations. A systematic review of PTA with or
without stenting demonstrated primary patency
rates at 12 months of 71.1% for PTA plus stenting
and 58.3% for PTA alone.15 This limits the utility
of PTA and necessitates repeat treatments with
attendant risks, complications, and costs. On the
other hand, evidence shows that SEP is superior to
best medical therapy and unsupervised exercise.16
A Cochrane Review showed that SEP resulted in
increased walking distances,6 while a meta-analysis
suggested that the most effective SEPs involveexercising to the point of maximal claudication
pain, with sessions lasting longer than 30 minutes,
three times per week for at least 3 months.14
Comparisons of SEP and PTA are relatively scarce
and are often limited by small sample size. A system-
atic review comparing SEP and PTA in claudicants
demonstrated that PTA resulted in a greater increase
in ABI but similar improvements in QoL. However,
none of the included studies directly compared SEP
and PTA.17-24There is no published literature of
a three-way comparison between SEP, PTA, and
SEP + PTA; thus, this study is the first of its kind.AnalysisIndividual analysis of outcome indicators is as
follows.
Table VI. Results of intergroup analysis at 3 months for clinical and QoL variables
SEP PTA PTA + SEP
PRWD (m) 400 (100e800)* 500 (200e1000) 880 (325e1000)*
ABIRe 0.80 (0.65e0.94)* 0.84 (0.69e0.99)a 0.97 (0.78e1.00)*,a
ICD (m) 61.2 (24.9e165.6)* 59 (33e96)a 108 (40e207)*,a
MWD (m) 92.8 (49.3e207.0) 87 (61e207)a 207.0 (71.4e207.0)a
ABIPE 0.50 (0.33e0.71)* 0.57 (0.35e0.77)a 0.68 (0.54e0.91)*,a
SF-36 PF 55 (27e75) 52 (35e75) 60 (36e79)
SF-36 RP 25 (0e100) 25 (00e75)a 75 (25e100)a
SF-36 BP 55 (32e75) 61 (38e84) 62 (42e74)
SF-36 GH 60 (42e72) 54 (35e76) 62 (47e67)
SF-36 V 50 (35e70) 55 (35e70) 55 (40e70)
SF-36 SF 75 (50e100) 88 (50e100) 75 (50e100)
SF-36 ER 83 (0e100) 100 (0e100) 83 (33e100)
SF-36 MH 72 (62e92) 82 (67e92) 82 (65e92)
SF-36 Index 0.64 (0.57e0.79) 0.63 (0.57e0.76) 0.68 (0.60e0.75)
VascuQol 5.24 (4.08e6.16) 5.36 (4.51e6.52) 5.80 (4.88e6.40)
See text for abbreviations.
*ManneWhitney U test, p< 0.05, SEP vs. PTA + SEP.
aManneWhitney U test, p< 0.05, PTA vs. PTA + SEP.
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PRWD over the 3-month duration of the study
with the smallest increase seen in SEP group and
the greatest increase seen in PTA + SEP patients, it
has been previously demonstrated that PRWD is
a subjective measure and correlates poorly with
QoL.8
 ABIRe. Increases in the ABI with PTA and
PTA + SEP are expected and self-explanatory.
However, ABI increase in SEP group is not in
agreement with previous studies.4,25 It is possible
that patients with SFA disease undergo a process
of remodeling of collateral circulation. Although
establishment of collateral pathways to improve
ABIRe is unlikely to happen within 3 months,
there is a possibility that such pathways may
have been established in these patients as
a consequence of ongoing ischemia, and SEP
leads to dilatation or expansion of these already
present collaterals. This, however, needs further
investigation.
 ICD and MWD. As both ICD and MWD were
significantly improved within each of the three
groups over the 3-month duration of the study,
the three different intervention regimens are
broadly equivalent in clinical terms. MWD is the
most reliable subjective measure of treatment
outcome. PTA + SEP patients performed better in
all clinical indicators except in MWD. However,
our data were censored at 207 m, introducing
a ceiling effect. PTA + SEP patients undergoing
treadmill exercise testing at3monthspostinterven-
tion were mostly symptom free at 207 m and indi-
cated a willingness to continue on the treadmillbeyond that point. Full walking to absolute claudi-
cationmaydemonstratea difference; however, this
can be difficult to achieve due to time limitations.
 QoL.As IC isbydefinitionacondition that isneither
limb nor life threatening, the primary goal of treat-
ment for IC is improvement in quality of life. Estab-
lishing the impact of treatment on QoL has been
difficult because of the small number of studies
with complete information. Previous studies on
SEP for treatment of IC have shown improvements
inQoL following treatment.9,14,26 Similarly, PTAhas
been previously studied and shown to be beneficial
to QoL.18-20,27 However, ours is the first study to
directly compare QoL following PTA and SEP in
the treatment of IC. Ours is also the first study to
directly compare these two treatments against
combined therapy (PTA+ SEP).
In previous studies, the subjective benefits of PTA
have not been sustained, often being lost by 1 year
compared to SEP.4,27 In our study, the three groups
of patients show very similar QoL benefits post
intervention. However, the two interventions
including SEP seemed to have additional benefits
in the psychological SF-36 domains (V, RE, MH).
No intervention had any impact on the SF-36
domain of GH. Given the recorded improvements
in other domains with all three treatments, the val-
idity of this domain has to be seriously questioned.Complications and AttritionThe 3-month PTA patency rate was 93.9% in our
study. There were no complications associated
78 Mazari et al. Annals of Vascular Surgerywith SEP orwith PTA in any of the three groups. The
dropout rate and unwillingness of some patients to
participate arose from distance between their homes
and hospital and unavailability of transportation.
The development of a community-based SEP may
improve treatment compliance, and a recent study
has demonstrated the efficacy28 and the cost-
effectiveness of such an approach.9Study LimitationsOur study has a few limitations. First, femoropopli-
teal disease represents 15% to 20% of the total
claudicant population. This makes it a relatively
pure sample. However, this is the group where the
treatment decisions are disputed. Therefore, we
wanted to study the difference in treatment
outcomes in this particular population. Second, as
the study predates the TASC grading system for fem-
oropopliteal lesions, we did not classify patients
prospectively into these categories. This policy was
maintained throughout the recruitment process
for uniformity. However, a retrospective TASC
grading is currently under way, and we should be
able to report that with the long-term results. Third,
the ICD and MWD were capped at 5 minutes,
making it difficult to assess the true improvement
in the absolute distances. However, the fixed load
treadmill testing used in this study is a standard
practice in modern vascular clinical practice, and
the obvious time constraints in outpatient clinics
justify this as a realistic compromise. And finally,
we acknowledge that patient follow-up is relatively
limited in this study but is continuing and we hope
to report longer-term follow-up in due course.
However, results thus far demonstrate interesting
findings that may influence the management of
patients with IC.Third Party and Insurance ImplicationsThe cost effectiveness of SEPs has been established
in previous studies.9 However, there are no commu-
nity-based SEPs currently available in NHS to
support this type of intervention. Provision of these
services is rarer in insurance-based health care
systems like the United States as they are not
covered by most of the insurance providers. We
found this to be a major barrier in our study popula-
tion as well, as most of the patients declined to take
part or dropped out because of unavailability of
these services in community, fiscal and time
expense of traveling to hospital, and commitment
to a hospital-based intervention program. These
difficulties can be overcome by provision of these
services at primary care level. This can providea cheaper alternative to PTA, thus reducing the
cost of intervention and re-intervention by
providing a more holistic improvement in lifestyle
rather than providing a ‘‘nondurable quick fix solu-
tion.’’ Further cost effectiveness studies need to be
undertaken in this field, and we aim to undertake
such analysis on conclusion of this trial.CONCLUSIONS
The early findings of this study and those preceding
it support the continued provision of SEP in the
treatment of IC, whether as monotherapy or
combined with PTA. Maximal treatment benefit
can be achieved by combining PTA and SEP in
patients with intermittent claudication due to femo-
ropopliteal disease. However, community-based
SEPs can provide a cost-effective first-line treatment
for these patients.
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